AbbVie Inc. (ABBV)

68.08
0.46 0.67
NYSE : Health Technology
Prev Close 68.54
Open 68.50
Day Low/High 67.84 / 68.75
52 Wk Low/High 65.06 / 100.23
Volume 9.96M
Avg Volume 8.84M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 101.33B
EPS 3.70
P/E Ratio 19.15
Div & Yield 4.28 (5.95%)
Play Strong Defense With 3 Big Biotechs

Play Strong Defense With 3 Big Biotechs

They offer impressive free cash flow, great balance sheets, evolving pipelines and nice dividend yields.

Stocks Continue to Sink

The market's major indices are getting worse as the morning progresses. There are deep losses across the board, with the Nasdaq Composite down nearly 3% at last check. Maybe we'll get some relief from the European markets closing. Oil is holding its...

Stocking Up on Cheap Biotech Stocks

Stocking Up on Cheap Biotech Stocks

In a year's time, investors may look back and think this was a great entry point.

What to Watch When 3 Big Biotechs Report

What to Watch When 3 Big Biotechs Report

Celgene, AbbVie and Gilead are set to report earnings. Here's what to look for.

3 Things the Market Needs to Get Off the Mat

3 Things the Market Needs to Get Off the Mat

The year has not started the way most pundits and prognosticators had envisioned.

3 Scorned Biotechs Destined to Rebound

Each of these small-caps delivered good news recently, only to have their stocks decline.

3 Scorned Biotechs Destined to Rebound

3 Scorned Biotechs Destined to Rebound

Each of these small-caps delivered good news recently, only to have their stocks decline.

Cheap Big-Cap Stocks That I Like for 2016

Cheap Big-Cap Stocks That I Like for 2016

It was all about the FANGs in 2015, but go for value plays this year.

Shire to Acquire Biopharma Company Baxalta in $32B Deal

Shire to Acquire Biopharma Company Baxalta in $32B Deal

Ireland’s Shire has clinched Baxalta with a stock and cash deal worth $32 billion on Monday.

2016 Outlook: FANGs Bite as Value Plays Gain

2016 Outlook: FANGs Bite as Value Plays Gain

Look for market leadership to shift as the U.S. economy plods along.

Have a CIGAR, You'll Go Far in 2016

Have a CIGAR, You'll Go Far in 2016

5 biotech stocks that could outperform the overall market in 2016.

Avoid These Investment Mistakes in 2016

Avoid These Investment Mistakes in 2016

Don't catch falling knives, and don't ignore dividends.

3 Biotech Stocks to Buy into 2016

3 Biotech Stocks to Buy into 2016

GILD, CELG and ABBV will lead the biotech resurgence.

AstraZeneca to Pay $4 Billion for 55 Percent of Acerta Pharma

AstraZeneca to Pay $4 Billion for 55 Percent of Acerta Pharma

United Kingdom-based AstraZeneca agreed to acquire a 55% stake in Dutch Acerta Pharma in a $4 billion deal, the company announced on Thursday.

Cramer: Dow Chemical-DuPont Merger Will Instantly Create Value

The merged company can become multiple companies.

6 Dowdy Drug Stocks to Consider for 2016

6 Dowdy Drug Stocks to Consider for 2016

History indicates pharmaceutical companies with low multiples offer payoffs down the road.

Stocks to Watch for 2016 M&A Deals

Stocks to Watch for 2016 M&A Deals

Look for 2015's record run of mergers and acquisitions to continue.

Don't Abandon the Biotech Ship

There's too much good out there.

Apple and 3 Other Dirt-Cheap Stocks That Investors Could Buy in 2016

Here is where to find value next year.

Apple and Other Dirt-Cheap Stocks

Apple and Other Dirt-Cheap Stocks

Here is where to find value next year.

Gilead Leads a Biotech Rally

The sector saw solid performance this week as the biotech juggernaut mounted a long-overdue rally.

Gilead Leads a Biotech Rally

Gilead Leads a Biotech Rally

The sector saw solid performance this week as the biotech juggernaut mounted a long-overdue rally.

2 Safe and Cheap Health Care Stocks

2 Safe and Cheap Health Care Stocks

These two will continue to churn out earnings growth.

AbbVie and Michael Kors Rally Amid a Mixed Market

The market has strengthened some since my last update. Apple (AAPL) definitely seems to acting better since its earnings report, and is back above some important moving-day averages. Jim Cramer is right about the stock -- it's one you should hold, n...

3 Health Care Names With Healthy Outlooks

3 Health Care Names With Healthy Outlooks

AbbVie, Teva and Zimmer Biomet posted solid quarters and are upbeat about the road ahead.

Hewlett Packard Split Gets Analysts' Attention; Abbvie Gets Upgraded

Hewlett Packard Split Gets Analysts' Attention; Abbvie Gets Upgraded

In Monday's analysts' actions, one Wall Street firm is weighing in on the Hewlett Packard split and another firm is giving Abbvie (ABBV) a rating and target price boost.

Abbvie upgraded at Morgan Stanley

Closing Bell: AbbVie Climbs on Sales Jump; Stocks Up in October

Closing Bell: AbbVie Climbs on Sales Jump; Stocks Up in October

Stocks ended slightly lower Friday, but enjoyed their best monthly gain in four years in October.

It's One Yawner of a Trading Day

Markets are now up slightly in what is one of most listless trading sessions to end a month that I recall lately. Not much moving.  As previously noted, AbbVie (ABBV) might be the standout in the S&P 500 today. It's up more than 10% in trading today...

3 Stocks to Watch Today

Futures are up as we get less than an hour from the opening bell for October's last trading day. Earnings reports continued to hit fast and furious this morning, as about one third of S&P 500 companies report quarterly numbers this week. Here are th...